Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

MLA

Long, Georgina V., et al. “Standard-Dose Pembrolizumab in Combination with Reduced-Dose Ipilimumab for Patients with Advanced Melanoma (KEYNOTE-029): An Open-Label, Phase 1b Trial.” The Lancet. Oncology, 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1367448978&authtype=sso&custid=ns315887.

APA

Long, G. V., Long, G. V., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., Hwu, W.-J., Hodi, F. S., Menzies, A. M., Guminski, A. D., Kefford, R., Kong, B. Y., Tamjid, B., Srivastava, A., … Carlino, M. S. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet. Oncology.

Chicago

Long, Georgina V, Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, et al. 2017. “Standard-Dose Pembrolizumab in Combination with Reduced-Dose Ipilimumab for Patients with Advanced Melanoma (KEYNOTE-029): An Open-Label, Phase 1b Trial.” The Lancet. Oncology. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1367448978&authtype=sso&custid=ns315887.